Search

Displaying results 9311 - 9320 of 9686 in total
  1. Drug

    Human Interleukin 8

    go.drugbank.com/drugs/DB16456
    Investigational

    Interleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).

  2. Drug

    Ezurpimtrostat

    go.drugbank.com/drugs/DB16458
    Investigational

  3. Drug

    TD-0903

    go.drugbank.com/drugs/DB16463
    Investigational

    TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants

  4. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)

  5. Drug

    Meplazumab

    go.drugbank.com/drugs/DB16465
    Investigational

    Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.

  6. Drug

    Polyinosinic-polycytidylic acid

    go.drugbank.com/drugs/DB16467
    Investigational

  7. Drug

    LSALT Peptide

    go.drugbank.com/drugs/DB16472
    Investigational

  8. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components. … Inbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein.

  9. Drug

    SAB-185

    go.drugbank.com/drugs/DB16491
    Investigational

  10. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.